Development of oral eflornithine for late-stage African sleeping sickness
Eflornithine is one of only three main-stay drugs registered for the treatment of late-stage human African trypanosomiasis, a uniformly fatal disease if left untreated. Eflornithine is currently recommended as a first line treatment, but due to its complicated intravenous administration, numerous patients are left untreated. A simplified mode of administration would enable more patients having access to treatment. Eflornithine is available as a racemate, a 50:50 mixture of its complementary stereoisomers. L-eflornithine is about 10-20-fold more potent but its absorption after oral dose is less favoured compared with D-eflornithine. The project will explore by non-clinical in vitro, in vivo and pharmacometric methods, a simplified, oral treatment alternative for eflornithine chemotherapy in late-stage T.b. gambiense sleeping sickness by seeking ways to improve the oral absorption of L-eflornithine.
- Project ID
SE-0-SE-29-2016-05780_2-285-12182- Activity status
- 2 - Implementation
- Aid type
- D02 - Other technical assistance
- % to Uganda
- 100.00
Organisations
- Funding
- Sweden
- Extending
- The Swedish Research Council
- Implementing
- Göteborgs universitet
Disbursements by fiscal year, quarter
| Fiscal year |
Fiscal quarter |
Value (USD) |
Uganda Value (USD) |
| 2017 |
Q2 |
39,000.04 |
39,000.04 |
Commitments by fiscal year, quarter
| Fiscal year |
Fiscal quarter |
Value (USD) |
Uganda Value (USD) |
| 2016 |
Q3 |
117,000.12 |
117,000.12 |
MTEF projections by fiscal year
| Fiscal year |
Value (USD) |
Uganda Value (USD) |
| CRS code |
% |
|
Medical research
(12182)
|
100.0
|